Endpoints Weekly covers Q1 earnings from major pharma companies, with focus on tariff concerns. FDA's Makary discusses new rare disease pathway, and HuidaGene reports first brain CRISPR treatment.

Amgen is the latest in a series of biopharma companies to tout a massive new US-based investment in manufacturing.

Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...

HHS Secretary Robert F. Kennedy Jr. said Friday that 35 states had signed up to participate in a new payment model meant to ...

In an interview with PBS' 'NewsHour' co-anchor and co-managing editor Amna Nawaz on Thursday, Marty Makary expanded on his ...

A federal district court in Texas on Thursday denied a request for a preliminary injunction from the Outsourcing Facilities ...

ALX On­col­o­gy’s ef­forts to progress a CD47 com­bo hit a ma­jor speed bump. The com­pa­ny said Fri­day that two tri­als ...

Nicholas Johnston launches Alis Biosciences, targeting struggling biotechs with $30B in trapped capital and aiming to return ...

When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing ...

Merck KGaA in talks to acquire SpringWorks Therapeutics for $47/share ($3.5B), gaining cancer drugs Ogsiveo and Gomekli. Deal ...

Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer ...

One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again ...